Physician profile
Megan Keyes
NPI 1790542264
$1,582.07
in general payments reported to CMS, 2019-2025
27 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $360 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $203.87 | 2024-2025 | Camzyos, Eliquis |
| Amgen INC. | $170.89 | 2024-2025 | Repatha, Tepezza, Repatha |
| Astrazeneca Pharmaceuticals Lp | $105.58 | 2025 | Farxiga |
| Xeris Pharmaceuticals, INC. | $103.38 | 2024-2025 | Recorlev |
| Esperion Therapeutics, INC. | $101.24 | 2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.97 | 2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $86.42 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $77.14 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $73.31 | 2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $57.45 | 2024-2025 | |
| Scpharmaceuticals INC. | $50.97 | 2025 | |
| Inspire Medical Systems, INC. | $46.39 | 2025 | Inspire |
| Lilly USA, LLC | $45.99 | 2025 | Jardiance |
| Cequr Corporation | $38.00 | 2025 | Cequr Simplicity |
| Novo Nordisk INC | $37.31 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $35.68 | 2025 | |
| Heartflow, INC. | $29.57 | 2025 | |
| Medtronic, INC. | $28.92 | 2024 | Minimed 780g |
| Ionis Pharmaceuticals, INC. | $25.03 | 2025 | Tryngolza |
| Lexicon Pharmaceuticals, INC. | $24.92 | 2024 | |
| Pfizer INC. | $23.49 | 2025 | |
| Tolmar, INC. | $21.96 | 2025 | Jatenzo |
| Bracco Diagnostics INC. | $20.98 | 2025 | |
| Agios Pharmaceuticals, INC. | $20.67 | 2025 | Pyrukynd |
| Janssen Pharmaceuticals, INC | $20.02 | 2024 | Xarelto |
| Edwards Lifesciences Corporation | $17.14 | 2025 | Sapien 3 Ultra Resilia |
| Recordati_rare_diseases_inc. | $15.78 | 2025 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Keyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.